重组人促红细胞生成素（rHuEPO）对与骨髓化生相关的获得性纯红细胞再生障碍性贫血（PRCA）患者输血依赖的缓解作用
Resolution of transfusion dependence by recombinant human erythropoietin (rHuEPO) in acquired pure red cell aplasia (PRCA) associated with myeloid metaplasia.
作者信息
Zeigler Z R, Rosenfeld C S, Shadduck R K
机构信息
Western Pennsylvania Cancer Institute, Western Pennsylvania Hospital, Pittsburgh 15224.
出版信息
Br J Haematol. 1993 Jan;83(1):28-9. doi: 10.1111/j.1365-2141.1993.tb04626.x.
Abstract
A patient with acquired pure red cell aplasia and agnogenic myeloid metaplasia (AMM) was treated with rHuEPO. She became transfusion independent. Weekly injections of rHuEPO have maintained the response without side-effects or disease progression. In addition, marrow fibrosis and splenomegaly have decreased. Therefore, rHuEPO may be effective therapy for some patients with acquired PRCA and/or AMM.
摘要
一名获得性纯红细胞再生障碍性贫血和原发性骨髓纤维化（AMM）患者接受了重组人促红细胞生成素（rHuEPO）治疗。她不再需要输血。每周注射rHuEPO维持了疗效，且无副作用或疾病进展。此外，骨髓纤维化和脾肿大有所减轻。因此，rHuEPO可能是治疗某些获得性PRCA和/或AMM患者的有效疗法。
Zotero 插件